Regeneron Pharmaceuticals, Inc.
807.65USD
-2.6600 (-0.33%)
Fetching financial statements from SEC filings…
| In $M except per-share | Q2 FY26 | Q1 FY26 | Q4 FY25* | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24* | Q3 FY24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 4,291 | 3,605 | 3,884 | 3,754 | 3,676 | 3,029 | 3,789 | 3,721 |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Operating Income | 1,294 | 643 | 880 | 1,027 | 1,080 | 592 | 990 | 1,180 |
| Net Income | 1,297 | 727 | 845 | 1,460 | 1,392 | 809 | 918 | 1,341 |
| EPS (Diluted) | $12.23 | $6.75 | $7.87 | $13.62 | $12.81 | $7.27 | $8.11 | $11.54 |
* Derived period (computed from FY minus reported quarters). Source: SEC filings (EDGAR)